Deloitte.


New Eminence Release

How quality in MedTech became a driver of financial performance

Christian Schiel, Sophia Hanau

November 2023

Deloitte.



More than 'license to operate' How quality and regulatory compliance in MedTech became a driver of financial performance

MedTech companies reporting quality and regulatory deficiencies not only struggle to ensure patient safety. There is also a long-term impact of such deficiencies and product recails on a company's competitive financial performance, which we analyze in this paper. While the stock markets did not seem to systematically punish poor quality and regulatory compliance in the MedTech sector in recent decades, our analysis finds that this has completely changed in the past flewyears. We now see a dramatically widening gap in stock market performance that can be associated with good and poor quality and regulatory compliance. In this paper, we discuss reasons for this shift and illustrate how MedTech companies are responding with tragesed investments.



Guest Speakers

Deloitte.



Dr. Christian Schiel

Partner at Deloitte Industry Lead Life Science & Healthcare - Risk Advisory Germany




Sophia Hanau

Manager at Deloitte MedTech Practice - Risk Advisory Germany


THE CHALLENGE | Are QA and RA perceived as a performance enablers? **Deloitte.**



THE CHALLENGE | Are QA and RA perceived as a performance enablers? **Deloitte.**









"The costs of poor quality are tangible, and their effect will cost you money, customers, and ultimately the success of your business."¹

Subir Chowdhury

THE STUDY | No evidence for systematic market penalty for poor quality prior to 2018




Fig. 1 - Cumulative weighted increase of market capitalization

- 30% of the companies with the lowest relative number of recalls
- 30% of the companies with the highest relative number of recalls
- All analyzed companies

THE STUDY | In recent years a value gap has been widening significantly




Fig. 1 – Cumulative weighted increase of market capitalization

- 30% of the companies with the lowest relative number of recalls
- 30% of the companies with the highest relative number of recalls
- All analyzed companies

Research Method:

The value gap is widening


Our study included all companies that were continuously represented in the Dow Jones U.S. Select Medical Equipment Index from 2012 to 2022. This resulted in a list of 40 medical device companies in our research scope. For each of these companies we then identified the number of recall events related to a medical device product as disclosed on the FDA website during the observed time period. We then sorted the companies by the number of recalls and corrected for company size effects by measuring relative recall frequency as 'number of recall events per one million USD of revenues' instead of using the absolute number of recall events. We used the companies' market capitalizations to measure and compare their financial performance over the observed time frame. Finally, we compared financial performance of groups of companies with a higher-than-average versus lower-than-average number of relative recall events using the weighted cumulative increase of their respective market capitalizations.

THE STUDY | Speculating about reasons for the widening value gap

- Changing **regulatory environment** in the MedTech industry (EU MDR, IVDR, UDI, serialization, ISO 13485 and more)
- Increased **public awareness and media coverage** of adverse events, product safety concerns and lacking supply chain traceability
- Increasing **product complexity and interconnectivity** combined with growing pressure to achieve a rapid market launch
- **Cybersecurity vulnerability associated with** innovative device categories (e.g. SaMDs)
- **Globalization of design requirements** companies have to incorporate requirements from more and more markets into the design and manage changes continuously.
- **M&A activity** in the sector may lead to increasingly fragmented and siloed management systems, IT architectures and data landscapes
- **Portfolio effects**: 'firms with [...] broader product portfolios have a higher likelihood of device recalls'.
- → A company's ability to consistently meet quality and regulatory requirements has clearly become a strategic differentiator in the MedTech sector.



THE STUDY | Design controls and labelling lead the list of root causes for FDA recalls





THE STUDY | Quality is a critical factor explaining systemic weaknesses





Fig. 3 – CFR citations of 'device' related FDA warning letters

THE CHALLENGE | How to smartly invest in quality & regulatory compliance?



- 30% of the companies with the lowest relative number of recalls
- 30% of the companies with the highest relative number of recalls
- All analyzed companies

THE CHALLENGE | How to invest in 'good quality'?



From documents to data and automated workflows





Increasing the agility and speed of controlled changes



Moving from reactive to preventive quality



Risk-based approach and Quality by Design



Providing on-demand guidance for employees



Unchaining AI for use at scale in regulated processes to leverage AI validation models



Balancing Local and Global Governance



Role-specific, on-demand training instead of `read and understand`

THE STUDY | The study is available for download

Deloitte.



More than 'license to operate' How quality and regulatory compliance in MedTech became a driver of financial performance

MedTech companies reporting quality and regulatory deficiencies not only struggle to ensure paties ratios, there is also a long-term impact of such deficiencies and product recails on a company's comparitive financial performance, which we analyse in this paper. While the stock markies did not seem to systematically punish poor quality and regulatory compliance in the MedTech accor in recard fice-acties, our analysis finds that this has completely changed in the past few years. We now see a dramatically widening gap in stock markee performance that can be associated with good and poor quality and regulatory compliance. The data indicates that the ability to consistently meet quality and regulatory compliance. The data indicates that the ability to consistently meet quality and regulatory differentiace, in this paper, we discuss reasons for this shift and illustrate how MedTech companies are responding with targeted investments.



Scan the QR Code below:




DELOITTE | We deliver end-to-end business transformations in the GxP regulated space


Deloitte is the largest professional services firm in the world and a leading transformation advisor for GxP regulated management systems in Life Sciences.



"We build smart GxP solutions for our clients to navigate regulatory complexity."

Dr. **Christian** Schiel Partner and Risk Advisory Industry Lead for Life Science & Healthcare





Let's talk!

Author



Christian Schiel Life Science & Healthcare Leader Risk Advisory Germany cschiel@deloitte.de

Global Contacts

Global MedTech Lead Glenn Snyder gsnyder@deloitte.com

Belgium Michel de Ridder mideridder@deloitte.com

Germany MedTech Cyber Carsten Heil cheil@deloitte.de

Italy Tommaso Stranieri tstranieri@deloitte.it

Switzerland Doug McKinnell dmmckinnell@deloitte.ch

UK

Andrew Flockhart aflockhart@deloitte.co.uk The Netherlands Aida Demneri ademneri@deloitte.nl

ttatsuoka@tohmatsu.co.jp

Tetsuyuki Tatsuoka

United States Oliver Steck osteck@deloitte.com

Japan

EMEA MedTech Lead Michael Dohrmann mdohrmann@deloitte.de

Central Europe Pavel Nevicky pnevicky@deloittece.com

India Muthukumarasamy Karuppiah mkaruppiah@deloitte.com

Deloitte.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entities is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/de/UeberUns to learn more.

Deloitte provides industry-leading audit and assurance, tax and legal, consulting, financial advisory, and risk advisory services to nearly 90% of the Fortune Global 500[®] and thousands of private companies. Legal advisory services in Germany are provided by Deloitte Legal. Our people deliver measurable and lasting results that help reinforce public trust in capital markets, enable clients to transform and thrive, and lead the way toward a stronger economy, a more equitable society and a sustainable world. Building on its 175-plus year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte's approximately 415,000 people worldwide make an impact that matters at www.deloitte.com/de.

This communication contains general information only, and none of Deloitte GmbH Wirtschaftsprüfungsgesellschaft or Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms or their related entities (collectively, the "Deloitte organization") is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.

Meet Your Presenters:



Presenter

Taylor Holcomb Solutions Engineer



Moderator

Chris Rush Solutions Engineer

Quality is the best business plan.

61% of industry professionals still only focus quality management efforts on ensuring compliance over establishing **quality as a strategic advantage.**

Quality's Impact to the Bottom Line

Save

Drive operational efficiencies throughout your organization

Scale

Get started quickly and grow faster with a quality system that allows you to scale and navigate different international markets

A Mitigate Risk

Improve the quality of regulatory submissions, be audit-ready, and achieve peace of mind knowing your quality system can stay ahead of compliance changes

62%

Of QA/RA professionals consider ensuring compliance to a regulatory body as a top objective for 2023

1 in 3

corporate executives see upgrading systems and processes as a top priority



Embracing Technology for Better Quality

Only 30%

of pre-market companies say they are "very confident" their current quality system can handle projected growth over the next 12 months

Out with the old

General purpose tools versus purpose-built solutions for companies with product(s) on the market

O What system/tool do you use for the following:

General purpose tools (e.g. paper, Excel, Word)	Tools for [blank] in general	Tools designed for medical device inc		Unsure		
Quality management						
	40%	18%			40	% 2 9
Design controls						
	46%		23%		27%	4%
Risk management						
		51%	19%		26%	4%
Complaint handling						
	37%	24%			34%	5%
Supplier management						
	48%		21%		23%	8%
Clinical testing						
	44%	22	.%	19%		15%
Continuous product developmer	nt					
	45%		29%		16%	10%
II		1		1		
0% 20%	40%			80%		10

Showing responses for pre-market companies only

ource: Greenlight Guru's 2023 Medical Industry Renchmark Stud

In with the new

Comparing companies that use general purpose tools vs. those that use purpose-built solutions:

Quality management

- 50% more likely to say they'll meet their quality objectives in 2023.
- 2x more likely to say documentation of design controls is "excellent".
- Nearly 2x more likely to say they'll meet their product development objectives in 2023.

Product development

- Over 2x more likely to say they include supply chain partners in design change discussions.
- Almost 3x more likely to say employee training oversight is fully automated (i.e., automated notifications rather than tracking via spreadsheets and searching for people who need additional training).

Risk management

 2x more likely to say their team's ability to view/ access real-time data for cross-functional collaboration is "very good" or "excellent".

Clinical data capture

 1.8x more likely to say employees have "high visibility" to access data and details about quality problems.

Source: Greenlight Guru's 2023 Medical Industry Benchmark Study

Greenlight Guru enables medical device companies to bring products to market faster, more efficiently, and with less risk.

1200+ of the world's leading MedTech companies trust Greenlight Guru



Partnering with an Industry-Specific QMS



- **Purpose-Built for MedTech** companies with validated workflows compliant with industry-specific regulations and requirements.
- An out-of-the-box system intuitively designed to get teams into a better system, faster.
- A **single source of truth** that breaks down information silos and drives alignment across your team
- End-to-end traceability that empowers teams and drives visibility that scales with you through each stage of your product lifecycle.

Achieve Peace of Mind Navigating Industry Regulations

Streamline compliance and gain peace of mind knowing that your workflows and systems are validated and compliant with industry-specific regulations and requirements.







For Quality Teams: Manage risk-based quality processes in a connected ecosystem that unites internal and external stakeholders

- 1. Automate your quality event workflows
- 2. Assure your team's documentation is up-to-date and audit ready
- **3.** Stay ahead of compliance changes
- Drive end-to-end traceability from design controls to post market surveillance

greenlight guru

Audits Risk Management SOP (SOP Source							
Risk Management SOP (SOP-01) Audit 🧳	Source Immediate Action	Investigation Root Cause	Action	Quality Review	Verification		
Visualize ()		X/////X///X///////////////////////////	(1)(1)(4)	///////////////////////////////////////	///////////////////////////////////////		
Description The Risk Management SOP needs to be reviewed to assure alignment with ISO 14971.	Sources			Stage	Complete		
Due Date Priority		Document	1	Document	1		
Oct 11, 2018 😑 Medium		Title		Title			
Audit Type Internal		P SOP-04 Ver. 0		@ SOP-4-3-2 Ver. 0			
		Description	Description		Description		
Assigned To		Risk Management	Risk Management		Internal Auditing Procedure		
2	+	Status		Status			
Reported To	Add Source	Superseded		Published			
2		Classification Procedure - Routed		Classification Procedure - Routed			
		Category			Category		
Reported On Date of Event Sep 26, 2018 Sep 26, 2018		9h Limmediate Action	Add New	96.0 Immediate Actions	Add New		
Initiated By		0 Investigation Tasks	Add New	O Investigation Tasks	Add New		
(models by							

"I highly recommend Greenlight Guru. They have taken a complex industry and made it into a product that is simple to use."



Tonia Bryant Director of Quality/Regulatory Lucerno Dynamics



Increasing the agility and speed of controlled changes




For Product Teams: Accelerate product development with a QMS that drives traceability throughout the entire product life cycle.

- Automatically maintain end-to-end traceability of your total product lifecycle
- 2. Auto-compile key design and risk documentation
- **3.** Demonstrate a risk-based approach to design

greenlight guru

4. Enhance collaboration to accelerate device development timelines



"Streamlining our agile development and design reviews with Greenlight Guru allowed us to create a compliant DHF and attain 510(k) clearance in 2 months - while ultimately saving team resources."



Victoria Enjamio VP of Operations BIOREP TECHNOLOGIES, INC.

Real Results from Real Customers

75%

reduction in time needed to set up a QMS **40%**

reduction in number of audit findings reduction in time spent on development & design documentation

50%

35%

reduction in time to market

Migrates from paper and overcomes failed eQMS implementation to scale into new markets and maintain compliance in global markets with Greenlight Guru



Company Size: 51-200 employees

Device Type/Class: Class I

Selling into: USA, Canada, Europe, Australia, Japan "Partnering with Greenlight Guru provides you with a team that's on your side, who are all medical device industry pros and understand what companies like ours go through."

> - Morris Sherwood, Person Responsible for Regulatory Compliance, Zyris

Streamlined quality and compliance efforts while accelerating product development timelines by 50% for their second-gen product.



Company Size: 11-50 employees

Device Type/Class: Class II

Selling into: USA (FDA)

"Greenlight Guru's software is **expensive on day one, and dirt cheap on day two**. This is a year's worth of someone's salary already done, implemented, and ready to go."

Daniel Powell, CEO, Spark Biomedical

Implemented an audit-ready QMS in just 3 months and successfully navigated 6 audits over the course of a year.



Company Size: 11-50 employees


Device Type/Class: Class I

Selling into: USA

The easy-to-follow onboarding and implementation process at Greenlight Guru allowed us to scale our business while implementing our new eQMS."

- Amanda Feddersen, QA Manager, MTI

Make Quality Your Strategic Advantage. We Can Help.



Get a free demo today at <u>https://www.greenlight.guru/bonus</u>



Moving MedTech Forward










blog & podcast in the industry

TRUSTED BY LEADING MEDTECH COMPANIES GLOBALLY





"Best QMS I have ever used ... "

"User-friendly EDC and esponsive support team"

"This is the easiest eQMS I have used in the 20 years I have been in the Medical Device Industry."

"The whole experience of using Greenlight Guru Clinical is accessible and user-friendly"

"Makes your QMS Simple and Effective"



Thank you Q&A